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Abstract
Background: Cervical cancer is the most common cancer among Indian women. The current
recommendations are to treat the stage IIB, IIIA, IIIB and IVA with radical radiotherapy and weekly
cisplatin based chemotherapy. However, Radiotherapy alone can help cure more than 60% of stage
IIB and up to 40% of stage IIIB patients.
Methods: Archival RNA samples from 15 patients who had achieved complete remission and
stayed disease free for more than 36 months (No Evidence of Disease or NED group) and 10
patients who had failed radical radiotherapy (Failed group) were included in the study. The RNA
were amplified, labelled and hybridized to Stanford microarray chips and analyzed using BRB Array
Tools software and Significance Analysis of Microarray (SAM) analysis. 20 genes were selected for
further validation using Relative Quantitation (RQ) Taqman assay in a Taqman Low-Density Array
(TLDA) format. The RQ value was calculated, using each of the NED sample once as a calibrator.
A scoring system was developed based on the RQ value for the genes.
Results: Using a seven gene based scoring system, it was possible to distinguish between the
tumours which were likely to respond to the radiotherapy and those likely to fail. The mean score
± 2 SE (standard error of mean) was used and at a cut-off score of greater than 5.60, the sensitivity,
specificity, Positive predictive value (PPV) and Negative predictive value (NPV) were 0.64, 1.0, 1.0,
0.67, respectively, for the low risk group.
Conclusion: We have identified a 7 gene signature which could help identify patients with cervical
cancer who can be treated with radiotherapy alone. However, this needs to be validated in a larger
patient population.
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Background
Cervical cancer is a preventable but the most common
cancer among Indian women and second most common
cancer among women worldwide [1,2]. More than
500,000 women are expected to develop the disease every
year worldwide. The tragedy is worsened by most of the
women presenting in locally advanced disease as well.
Human Papilloma virus has been identified as an impor-
tant factor in the development of cervical cancer, but it
alone is not sufficient and requires additional events [3].
Cervical cancer progresses through initial dysplastic or
pre-malignant stages before becoming invasive. The evo-
lution to an invasive cancer may take up to 15 years or
more [4]. PAP smear testing has been found to aid in early
detection of pre-malignant lesions, thereby preventing the
morbidity and mortality of cervical cancer. However,
organized screening is primarily available in the Western
countries and most of the developing countries including
India do not have an organized screening program.
The standard treatment currently recommended for stage
IIB, IIIA, IIIB and IVA has been concurrent chemo-radio-
therapy, usually with weekly cisplatin based chemother-
apy [5]. This is based on the data from 5 randomized trials
which had shown a 30 -50% benefit in reducing the risk
of death compared to the radiotherapy only arm. While
the addition of chemotherapy is clearly beneficial, not all
patients may need it. Currently, there are no reliable ways
of identifying the individuals who may respond to the
radical radiotherapy from those who will not respond.
The use of molecular approaches, such as gene expression
studies, has helped tailor treatment based on the molecu-
lar characteristics. The Oncotype Dx testing for breast can-
cer is an example of using the newer techniques to help
tailor the treatment to individual patient [6]. Several
potential markers for tumour response have been identi-
fied in the past, such as c-myc, Bcl2, Bax, HIF2α, Ki67
index, c-erbB2 [7-11]. However, most of these studies
were on smaller number of patients and have not been
used routinely to predict radiation response. More
recently a few studies have used microarray based technol-
ogy to identify gene signatures predictive of radiation
response [12-14] however, none of them had validated
their genes using further techniques such as Real time
Polymerase Chain Reaction (PCR).
Avoiding morbidity and the cost of chemo-radiation in
cervical cancer would be relevant particularly in a devel-
oping country. This study aims to develop a test which can
help identify patients who may not need chemotherapy
and who can be cured only with radical radiotherapy.
Methods
Archival total RNA extracted from punch biopsy samples
collected in RNA later (Ambion, Austin, Tx; Cat no:
AM7021) and stored in the tumour bank after an
informed consent were used, after obtaining the Institu-
tional Ethical committee's approval for the study. The
RNA had been extracted from the biopsy samples using
the RNeasy RNA extraction kit (Qiagen, Gmbh, Hilden;
Cat no: 74106) as per the manufacturer's instructions.
Twenty five patients' samples were included in the study.
The criteria for inclusion in the study were as follows: 1.
good quality RNA as assessed by Bio-analyser (RIN 6 or
above); 2. paired paraffin block having at least 70% tumor
cells; 3. sufficient quantity of RNA be available; 4. patient
should have completed prescribed radiotherapy and fol-
low-up information till death/last disease free status be
available.
All the patients had received radical radiotherapy, with 6
MV X-ray from Linear accelerator and brachytherapy with
HDR-Ir192. The total dose given was between 64 - 66 Gy,
over 56 - 60 days. The median and mean follow-up period
among the NED group was 43 months and 42 months,
respectively, with a minimum and maximum period of
follow up of 38 and 45 months, respectively. All the Failed
patients had been followed up till progression/relapse/
death. Complete remission refers to complete resolution
of measurable disease by clinical examination, hemato-
logic, biochemical or radiological examination; Partial
remission refers to 50% or more disease reduction lasting
longer than one month; Progression refers to worsening
or advancing disease.
HPV testing
The quality of the DNA was assessed by amplifying for β
globin prior to HPV testing which was done using GP5+
and GP6+ primers [15]. HPV16 and 18 typing was done
using Nested Multiplex Polymerase Chain Reaction
(NMPCR) technique [16]. SiHa DNA for HPV16, HeLa
DNA for HPV18 (positive controls) and C33A DNA (neg-
ative control) were included in all runs.
Microarray experiment
1 μg of total RNA from the tumour sample and universal
RNA (Stratagene; Cat no: 740000-41) were reverse tran-
scribed using Array script at 42°C for 2 hrs to obtain
cDNA using the Amino Allyl MessageAmp II aRNA ampli-
fication kit (Ambion, Austin, Tx; Cat no: AM1797). The
cDNA was amplified by in-vitro transcription in the pres-
ence of T7 RNA polymerase; aRNA thus obtained was
purified and quantitated in NanoDrop (NanoDrop Tech-
nologies, Wilmington, DE, USA). 20 μg of tumour aRNA
was labelled using NHS ester of Cy5 dye and control uni-
versal aRNA was labelled using NHS ester of Cy3 dye. The
Cy3 and Cy5 labelled aRNA was used for hybridization
onto the microarray chips from Stanford Functional
Genomics Facility (SFGF, Stanford, CA) containing
44,544 spots, for 16 hrs in Lucidea SlidePro hybridizationBMC Cancer 2009, 9:365 http://www.biomedcentral.com/1471-2407/9/365
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chamber (GE Health Care, Uppsala, Sweden) at 42°C.
After hybridization, slides were washed in 0.1× SSC, 1×
SSC followed by 0.1× SSC and dried.
The slides were scanned in ProScanArray (PerkinElmer,
Shelton, CT, USA). Griding was done using Scan array
Express software package (version -4). The integrated or
mean intensity of signal within the spot was calculated.
The files were saved as GPR files.
All the raw data files have been submitted to GEO with
an assigned GEO accession number - GSE14404.
Microarray data analysis
The Foreground Median intensity for Cy3 and Cy5, Back-
ground Median intensity for Cy3 and Cy5, spot size data
were imported into BRB-ArrayTools software [17] using
the Import wizard function. Background correction was
not done. Global normalization was used to median cen-
tre the log-ratios on each array in order to adjust for differ-
ences in labelling intensities of the Cy3 and Cy5 dyes. The
data was analysed using the Class comparison module in
the BRB-Array Tools software. The normalized Log ratios
were also imported into Significance Analysis of Microar-
ray (SAM) [18] software and analysed.
Class Comparison in BRB-Array Tools
We identified genes that were differentially expressed
among the two classes (NED VS Failed) using a random-
variance t-test. The random-variance t-test is an improve-
ment over the standard separate t-test as it permits sharing
information among genes about within-class variation
without assuming that all genes have the same variance
[19]. Genes were considered statistically significant if their
p value was < 0.0015. In addition a two fold difference
was required between the two classes.
SAM Analysis
The normalized log ratios of all the samples were
imported into SAM software and analysed. First a two
class unpaired analysis with 100 permutations was done.
A delta value of 0.96 and a fold difference of 2 was used
to identify the genes differentially expressed. In addition,
Survival analysis for significant genes was done using 100
permutations and with a delta of 0.85.
Quantitative Real time PCR
High Capacity Reverse Transcription kit (Applied Biosys-
tems, Foster City, CA; Cat no: 4368814) was used to
reverse transcribe 2 μg of total RNA from the 23 samples
in a 20 μl reaction volume. In two samples, due to the lim-
iting amount of RNA, 0.75 μg was used for the cDNA syn-
thesis.
These cDNA samples were used for real time PCR amplifi-
cation assays using TaqMan® arrays formerly TaqMan®
Low density arrays (TLDA) (Applied Biosystems, Foster
City, CA; Cat no: 4342261). The fluorogenic, FAM
labelled probes and the sequence specific primers for the
list of genes with endogenous control 18S rRNA were
obtained as inventoried assays and incorporated into the
TaqMan® array format. Quadruplicate (n = 23) and dupli-
cate (n = 2; with limiting amount of RNA for cDNA syn-
thesis) cDNA template samples were amplified and
analysed on the ABI Prism 7900HT sequence detection
system (Applied Biosystems, Foster City, CA).
The reaction set up, briefly, consisted of 1.44 μg of cDNA
template made up to 400 μl with deionised water and
equal amounts of TaqMan® Universal PCR Master Mix
(Applied Biosystems, Foster City, CA; Cat no: 4304437).
100 μl was loaded into each of the 8 ports of the array (2
ports comprise of one sample replicate on the array).
Thus, the samples run as duplicates were only loaded into
4 ports of the array. Thermal cycling conditions included
a 50°C step for 2 minutes, denaturation for 10 min at
94°C followed by 40 cycles consisting of 2 steps: 97°C for
30 seconds and 59.7°C for 1 minute for annealing and
extension.
The raw data from the Prism 7900HT sequence detection
system was imported into the Real-Time StatMiner™ soft-
ware for statistical analysis of the data. Among the endog-
enous reference genes included on the array (18S
ribosomal gene; UBC, β2 microglobulin), UBC was cho-
sen after visualizing the global Ct value distribution, for
normalizing the data (see Additional file 1). The TLDA
assays were run at LabIndia Instruments Pvt Ltd laborato-
ries at Gurgaon, New Delhi.
Development of the scoring method
Relative quantification is based on the relative expression
of a target gene versus a reference gene. The UBC normal-
ized Delta Ct values were imported into the Excel spread
sheet for obtaining the RQ values for the 24 samples (one
sample which had not worked in RQ-RT-PCR was
excluded), using each NED sample once as a calibrator.
The genes were provided a score of 2, if the RQ value was
>2. This analysis was done initially on all the selected
genes taken up for validation and then on genes which
had greater than two fold difference between the two
classes, with an attempt to obtain a group of genes which
can help distinguish between the two classes. The Mean
score, the standard error (SE), the mean score ± 1SE and
mean score ± 2SE were calculated and the Mean ± 2SE was
used for categorizing as either High risk or Low risk. The
cut-off was set at 40% (5.6) of the potential total score
possible.
Sensitivity is the probability for a NED sample to be cor-
rectly predicted as Low risk; Specificity is the probability
for a Failed sample to be correctly predicted as High risk;BMC Cancer 2009, 9:365 http://www.biomedcentral.com/1471-2407/9/365
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PPV is the probability that a sample predicted as Low risk
actually belongs to class NED; NPV is the probability that
a sample predicted as High risk actually does not belong
to NED [17].
Statistical Analysis
Kaplan Meier survival analysis was used to study the dis-
ease free survival (DFS) in the two classes, using the Stata
10 software. This was done initially based on the stage of
the disease and then based on the gene signature risk strat-
ification (Score ≤ 5.60 and score >5.60). Log rank test was
used to assess the survival difference.
Results
The patients' clinico-pathological status and their
response to treatment are given in Table 1. Twenty four of
the tumours were Squamous cell carcinomas (16 Large
cell non-keratinizing, 4 large cell keratinizing and 4
unspecified) and one was a poorly differentiated carci-
noma. Fourteen were HPV16 positive, 7 were HPV18 pos-
itive and 4 were HPV16 and 18 subtype negative (but HPV
positive).
Using different methods, as described above, genes that
were found to be differentially expressed between the two
classes (NED and Failed) were obtained. The List of genes
significant by different methods of analysis are given as a
Additional file 2.
Twenty genes were selected for further validation by RQ-
PCR using the Taqman Low Density Array card (TLDA)
format (Table 2). These 20 genes formed part of the 95
genes selected for analysis using the TLDA format. Most of
the additional genes were those which had been found to
be differentially expressed between cervical cancer and
normal cervix; cervical cancer and CIN1; CIN3 and CIN1;
CIN3 and Normal cervix. Apart from the mandatory
endogenous 18S rRNA included in the TLDA cards, based
on the microarray data, UBC and β2 microglobulin, were
included as additional endogenous reference genes.
One of the sample CXL19-hov160 which had worked in
microarray did not amplify in the RQ-TLDA assay and had
to be removed from further analysis. In addition, OPTC
and C11orf9 genes did not amplify in any of the samples.
Table 1: Clinico-pathological and disease free status of the patients
ID Stage Grade HPE Subtype HPV 
Subtype
Treatment 
given
Response Outcome 
(NED/
Failed)
Site of 
failure
DFS 
(months)
OS 
(months)
hoae145 IIB III SCC LCNK 16 RT CR NED 44 44
hoae146 IIB III SCC LCNK Negative RT CR NED 38 38
hoae152 IIIB III SCC LCNK 18 RT CR NED 45 45
hoae153 IIB III SCC LCK 16 RT CR NED 45 45
hov156 IIB III SCC LCNK 18 RT CR NED 43 43
HOV160 IIB III SCC LCNK 16 RT CR NED 44 44
HOV161 IIB III SCC LCNK 18 RT CR NED 41 41
HOV164 IIIB III SCC LCNK Negative RT CR NED 38 38
hov165 IIB III SCC Not 
specified
16 RT CR NED 43 43
hov182 IIA III SCC LCNK 16 RT CR NED 39 39
hov183 IIB III SCC LCNK 18 RT CR NED 45 45
hov189 IIA III SCC LCNK 16 RT CR NED 40 40
hov190 IB III SCC LCNK 16 RT CR NED 42 42
hov196* IIB II-III SCC LCNK 16 RT+CT PR Failed Local 0 6
hov198 IIA III SCC LCNK 16 RT PR Failed Local 0 13
hov199 IIB III SCC LCNK 18 RT CR Failed Distant 10 34
hov200 IIIB II-III SCC LCK 16 RT PR Failed Local 0 24
hov217 IIB III SCC LCNK 18 RT PR Failed Local 0 7
hov218 IIB III SCC LCNK Negative RT CR Failed Distant 18 23
hov220 IIB III SCC Not 
specified
16 RT PR Failed Local 0 11
hov232 IIA III SCC Not 
specified
16 RT CR NED 46 46
hov240 IIB III SCC LCNK 16 RT CR NED 38 38
HOV241 IIB III PD Not 
specified
Negative RT PR Failed Local 0 12
HOV242 IIIB II SCC LCK 16 RT PR Failed Local 0 15
hov247 IIB III SCC LCK 18 RT PR Failed Local 0 7
* - One patient had received concurrent chemo-radiotherapy and had failed, was also included in the study
NED = No evidence of disease; SCC = Squamous cell carcinoma; PD = Poorly differentiated; LCNK = Large cell non-keratinizing;
LCK = Large cell keratinizing; CR = Complete remission; PR = Partial remission; RT = Radiotherapy; CT = ChemotherapyBMC Cancer 2009, 9:365 http://www.biomedcentral.com/1471-2407/9/365
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The RQ values after calibrating with the NED samples
(Mean) for all the 95 genes showed two additional genes,
UBE2C and IGF2BP2, to be overexpressed in the Failed
samples compared to the NED samples. These two genes
had initially been chosen for validation of the differen-
tially expressed genes between cancer and normal cervix.
After excluding the genes which did not amplify, we now
had 20 genes for further analysis (see Additional file 3).
There were 10 genes (including UBE2C and IGF2BP2)
with more than 2 fold difference between the two classes.
In addition, 4 genes had a fold change between 1 and 2.
There was only 44% (8/18) concordance between the
microarray data and the Relative quantitation RT-PCR
data, when a 2 fold difference was used as the criteria. The
best concordant rates were with the SAM survival analysis,
wherein of the 11 genes taken up for validation, 8 were
concordant (73%).
We then tried to analyse the RQ data using each of the
NED sample once as a calibrator. The focus was on genes
which had an over-expression of at least two fold between
the two classes. A scoring system was then developed as
described in the Methods section. Using this we found
that the seven gene score (UBE2C, MMP3, DCUN1D5,
SDCCAG8, IGF2BP2, CCL18 and FST) can help distin-
guish between the Failed and the NED samples. Table 3
gives the mean score of the 24 experiments, the standard
deviation, the standard error (SE), and score ± 2SE (see
Additional file 4 for the details). Using a cut-off value of >
5.60, the sensitivity, specificity, positive predictive value
(PPV) and negative predictive value (NPV) are 0.64, 1.0,
1.0, 0.67, respectively, for the Mean ± 2SE. At this cut-off
point, 9 of the 14 (64) NED samples were classified as low
risk, while all the failed samples were classified as high
risk.
The Kaplan Meier survival curves are given in Figures 1
and 2, the former based on the stage of the disease and the
latter based on the gene expression signature.
Discussion
Cervical cancer although a preventable disease, still kills a
significant number of women. Most of the tertiary centres
in developing countries still see patients in advanced
stages. Radiotherapy has been the main stay of treatment
and the addition of concurrent cisplatin based chemo-
therapy has been found to improve cure rates. However,
not all patients will need concurrent chemotherapy,
which has its own cost implications and morbidity, partic-
ularly in a developing country. With the emphasis shifting
to tailoring therapy to individuals based on the patient
and tumour characteristics, it is essential to develop newer
tests which can help identify individuals who can be cured
only with radiotherapy. This paper provides one such
approach, wherein a seven gene score was found to help
distinguish those who are likely to be cured with radio-
Table 2: List of genes selected for RQ-RT-PCR validation
GENE SYMBOL GENE NAME ASSAY ID AMPLICON SIZE
TRAPPC6A trafficking protein particle complex 6A Hs00225487_m1 133
FLJ90231 Galactosidase, beta 1-like 3 Hs00293572_m1 109
MRCL3 myosin regulatory light chain MRCL3 Hs00272402_m1 105
ASB16 ankyrin repeat and SOCS box-containing 16 Hs00365575_m1 79
C11orf9 chromosome 11 open reading frame 9 Hs00203205_m1 56
PLA2G6 phospholipase A2, group VI (cytosolic, calcium-independent) Hs00185926_m1 89
YAP1 Yes-associated protein 1, 65 kDa Hs00371735_m1 64
BIRC2 baculoviral IAP repeat-containing 2 Hs01112284_m1 84
MMP3 matrix metallopeptidase 3 (stromelysin 1, progelatinase) Hs00968308_m1 98
FST follistatin Hs00246260_m1 105
DCUN1D5 DCN1, defective in cullin neddylation 1, domain containing 5 (S. cerevisiae) Hs00260376_m1 61
HCRTR1 hypocretin (orexin) receptor 1 Hs00173513_m1 78
TMEM123 transmembrane protein 123 Hs00364685_m1 56
ASPN asporin Hs00214395_m1 72
CCL18 chemokine (C-C motif) ligand 18 (pulmonary and activation-regulated) Hs00268113_m1 83
CTSC cathepsin C Hs00175188_m1 71
SDCCAG8 serologically defined colon cancer antigen 8 Hs00394864_m1 79
THOC6 THO complex 6 homolog (Drosophila) Hs00738020_g1 67
CES2 carboxylesterase 2 (intestine, liver) Hs00187279_m1 88
OPTC opticin Hs00205039_m1 71
IGF2BP2 insulin-like growth factor 2 mRNA binding protein 2 Hs01118009_m1 80
UBE2C ubiquitin-conjugating enzyme E2C Hs00738962_m1 91
The last 2 genes were found to be overexpressed in Failed to compared to NED samples, although they had been included initially as genes 
differentially expressed between the tumours/CIN3 and normal cervix.BMC Cancer 2009, 9:365 http://www.biomedcentral.com/1471-2407/9/365
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therapy alone from those who may require additional
forms of treatment.
The concordance between the microarray and the RQ-PCR
data on genes differentially expressed with more than 2
fold was 44% (8/18). SAM Survival analysis had identi-
fied 13 genes (of the 14 genes, one was a duplicate -YAP1)
as being differentially expressed and 11 of these genes
were included in our validation. One gene did not have a
suitable assay for the TLDA format. Of the 11 genes tested,
8 were found to be concordant in the RQ-RT-PCR valida-
tion (73% concordance rate). The SAM Survival analysis
had correctly identified 5 of the 7 genes which we had
used for the prediction.
One group had addressed the issue of concordance, when
they compared Affymetrix data with Real time quantita-
tive data for 48 genes. Their concordance rate was around
69% and they have reported that this may be usually due
to differences in the target transcripts being identified by
the two platforms (microarray versus Real time PCR) [20].
Klopp et al [14] had used microarray analysis on samples
obtained prior to treatment and 48 hours after start of
chemoradiation in 12 patients and found that a 58 gene
signature can help predict recurrence. Others have devel-
oped either a Lymph node prediction model using 156
gene signatures, which had a prediction accuracy of 77%
in predicting lymph node metastasis [21] or thermo-
radio-response prediction model using a 35 gene signa-
ture [22]. Wong et al [13] used supervised clustering anal-
ysis to classify radiosensitive and radioresistant tumours
in 13 patients.
Six of the seven genes, identified in our study, are known
to be involved in cancers, with some of them having a role
in inducing therapeutic resistance.
Insulin like growth factor 2 mRNA binding protein 2/
IGF2BP2/IMP2
This oncofetal protein functions by binding to the 5'UTR
region of IGF2 and thereby regulating its translation. Yis-
raeli (2005) [23] had suggested that the VICKZ family, to
which IGF2BP2/IMP2 belongs, have a role to play in cell
polarity and migration, cell proliferation and cancer.
Autoantibodies to IGF2BP2 has been detected in different
cancers including hepatocellular carcinoma [24,25].
IGF2BP2 was also found to be overexpressed in epithelial
ovarian cancers [26].
Ubiquitin-conjugating enzyme E2C/UBE2C/UBCH10
The gene is a member of the E2 ubiquitin-conjugating
enzyme family, playing key roles in regulation of cell
cycle. The gene was found to be overexpressed in cervical
Table 3: Scores based on RQ-RT-PCR values
MEAN SCORE STDEV SE SCORE+2SE SCORE-2SE
DCt.CXL103-HOV220 9.57 1.95 0.52 10.61 8.53
DCt.CXL108-HOV199 7.86 1.99 0.53 8.92 6.79
DCt.CXL120-HOV241 12.86 1.51 0.4 13.67 12.05
DCt.CXL121-HOV247 10 1.36 0.36 10.73 9.27
DCt.CXL17-HOV200 7.86 2.66 0.71 9.28 6.44
DCt.CXL46-HOV198 7.43 2.98 0.8 9.02 5.84
DCt.CXL86-HOV218 6.86 2.32 0.62 8.09 5.62
DCt.CXL90-HOV217 7.14 2.57 0.69 8.52 5.77
DCt.CXL95-HOV242 13.14 1.29 0.35 13.83 12.45
DCt.CXM018-HOV196 8.86 1.7 0.46 9.77 7.95
DCt.CXL111-HOV240 1.14 1.29 0.35 1.83 0.45
DCt.CXL13-HOV183 3.86 2.14 0.57 5 2.71
DCt.CXL14-HOV164 1.86 1.83 0.49 2.84 0.88
DCt.CXL16-HOV232 4.43 2.38 0.64 5.7 3.16
DCt.CXL20-HOV182 4.29 2.46 0.66 5.6 2.97
DCt.CXL22HOV161 3.71 2.7 0.72 5.16 2.27
DCt.CXL3-HOV165 5.57 2.85 0.76 7.09 4.05
DCt.CXL35-HOAE145 1.29 1.86 0.5 2.28 0.29
DCt.CXL52-HOAE152 4.29 1.9 0.51 5.3 3.27
DCt.CXL62-HOAE153 1.43 1.65 0.44 2.31 0.55
DCt.CXL73-HOAE146 3.43 2.98 0.8 5.02 1.84
DCt.CXL82-HOV189 4.86 2.32 0.62 6.09 3.62
DCt.CXL9-HOV156 4.57 3.18 0.85 6.27 2.87
DCt.CXL91-HOV190 2.57 1.99 0.53 3.63 1.51
Samples in bold are the failed samples;
STDEV = Standard deviation; SE = Standard errorBMC Cancer 2009, 9:365 http://www.biomedcentral.com/1471-2407/9/365
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cancers [27] and was reported to contribute to chemother-
apy resistance in breast cancer [28]. Donata et al [29] have
reported over-expression in low grade astrocytomas and
in glioblastomas, wherein they could contribute to thera-
peutic resistance.
Follistatin/FST
This protein inhibits follicle stimulating hormone release.
FST has been shown to be associated with Basal cell carci-
nomas [30]. In addition, integrin alpha6beta4, which is
involved in apoptosis resistance, invasion, metastasis, can
induce the expression of several genes, including FST,
which could help mediate these processes [31].
Matrix metallopeptidase 3 (stromelysin1; progelatinase)/
MMP3
MMP3 has been reported to be expressed in lymph node
metastasis and in recurrent cervical cancers [32]. MMP3
has been suggested to have a role in modulating chemo-
therapeutic response in head and neck cancers [33] and
has been shown to play a role in breast tumour carcino-
genesis [34].
Chemokine (C-C motif) ligand 18/CCL18/MIP4/AMAC/
DCCK1/PARC
CCL18/PARC has been found to be overexpressed in the
serum of acute lymphoblastic leukaemia patients [35] and
in the ascitic fluid of patients with ovarian carcinoma
[36].
Serologically defined colon cancer antigen 8/SDCCAG8/
Centrosomal colon cancer autoantigen protein/CCCAP
Autologous antibody responses to SDCCAG8 has been
reported in colon and ovarian cancers [37,38]. It is a pro-
tein integral to the centrosomes [39].
Defective in cullin neddylation 1, domain containing 5/
DCUN1D5
Little is known about the function of this gene, particu-
larly in cancer.
Conclusion
Locally advanced cancer of the cervix is now being treated
with chemo-radiotherapy. However, nearly 60% of stage
based on stage of disease Figure 1
Based on stage of disease.BMC Cancer 2009, 9:365 http://www.biomedcentral.com/1471-2407/9/365
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IIB and 40% of stage IIIB can be cured with radiotherapy
only. Currently there are no reliable ways of identifying
those patients who can be cured with radiotherapy alone.
Using microarray technique followed by Relative Quanti-
tation Real Time PCR (RQ RT-PCR), we have identified a
7 gene signature with differential expression between cer-
vical cancers with and without recurrence/progression
after radiation treatment. This finding needs to be vali-
dated in an independent larger patient population.
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